New quarterly report expected Apr 27, 2026. Report will refresh after results.
C
Crane Company
CR · Industrials
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
A Rare Industrial Moat Priced as If Perfection Is Already Delivered
The market has correctly identified that Crane's core businesses are exceptional — specification-driven, sticky, and structurally improving — but has stopped asking whether a 170-year-old valve-and-sensor manufacturer trading at a software-adjacent multiple can grow into that valuation while simultaneously integrating four acquisitions under a first-time public CEO. The quality is real; the price assumes the quality compounds from a base that may be cyclically elevated.
Flowly Score
Apr 16 Close
-27%$186.10
Fair Value
$135.00
50
Averageat $186.10
Business Strength7/10
Two genuine moat engines — aerospace certification lock-in and process flow spec-driven switching costs — running through a classic OEM-plus-aftermarket flywheel; Engineered Materials is the uninvited guest at this table, cyclical and commoditized, dragging on an otherwise exceptional industrial franchise. Margins in the low-forties are not luck — they're the fingerprint of a business that sells certification and qualification, not parts.
Financial Resilience7/10
Outside the 2022 restructuring artifact, this is a textbook clean cash converter — OCF reliably tracks earnings, CapEx barely grazes operating cash flow, and FCF margins are expanding, not compressing. The willingness to lever up to 3x for acquisitions introduces real execution risk, but a company starting from 1.1x with a growing cash generative base has meaningful room before this becomes a structural concern.
Growth & Trajectory7/10
The aerospace segment is in genuine momentum — a record backlog up a quarter year-over-year is a multi-year visibility signal, not a quarterly print — and the four sensor/detection acquisitions represent a coherent bet on expanding from components into proprietary sensing platforms. The chemical end-market weakness in Process Flow is the counterweight, expected to persist through the trough, and the North American geographic concentration means Crane can't reach for faster-growing demand pools to supplement when any domestic cycle softens.
Valuation2/10at $171.22
The multiple has roughly doubled from trough levels on a business whose fundamental character hasn't changed that dramatically — investors have discovered the quality and priced it in aggressively, leaving virtually no margin of safety across any reasonable DCF scenario. Even the optimistic case points to fair value below the current price, which means you need to believe in an outcome more optimistic than the optimistic case to generate a positive return from here.
Risk5/10
The single most concrete near-term risk is four simultaneous acquisitions integrating under a brand-new CEO inheriting the helm in April 2026 — that's a lot of organizational complexity to absorb at once, and any integration stumble arrives exactly when investors are paying a premium that requires flawless execution. The longer-cycle risk is platform mortality in aerospace: the moat on any given certified program is permanent until the program ends, and winning the next design cycle is never guaranteed.
This is a genuinely good industrial business — the switching costs in aerospace and process flow are real, durable, and quietly compounding through the aftermarket flywheel. The case for owning it is straightforward: Crane sells into applications where component failure costs infinitely more than the component, creating an embedded pricing premium that persists for program lifetimes. The problem is not the business — it's the spread between what the business is worth on reasonable assumptions and what you're being asked to pay. When even an optimistic growth scenario fails to justify the current price, the risk-reward calculus tilts unfavorably regardless of underlying quality. The next chapter is strategically coherent: acquiring sensing and detection capabilities in aerospace, nuclear, and industrial instrumentation is a logical extension of the existing moat — these aren't diversification moves, they're moat-deepening moves that should compound the certification lock-in advantage into new platform wins. Management's willingness to pay up for strategically aligned targets and to rename the core segment to reflect broader 'Advanced Technologies' ambitions signals a team thinking about what this business becomes over the next decade, not just optimizing what it is today. That clarity of purpose is worth something. The specific risk that keeps this from being an obvious long even at a lower price is simultaneous complexity: a new CEO, four acquisitions in various stages of integration, a chemical end-market that management has explicitly flagged as stuck in trough, and a valuation that assumes all four segments perform at or above expectations. New CEOs introduce strategic drift risk even in stable periods — during a year with this much operational change, the window for something to go wrong while the market is pricing nothing-goes-wrong is unusually wide.